Onconetix, Inc.
ONCOAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Maxim Group | downgrade | Buy →Hold | Sep 13, 2023 |
| HC Wainwright & Co. | maintain | Buy | Apr 26, 2023 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-45050.00| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-1.28 | $-4505.00 | $17.1K | $17.1K |
| May 13, 2026 | $-67.10 | — | $21.5K | — |
| Mar 13, 2026 | $10.40 | $-35700.00 | $303.6K | — |
| Nov 13, 2025 | $-312.50 | $-32300.00 | $303.7K | — |
| Aug 14, 2025 | $-202.50 | $-20400.00 | $106.5K | — |
| Jun 12, 2025 | $-1059.32 | $-34850.00 | $101.6K | — |
| Jun 2, 2025 | $-34000.00 | $-45050.00 | $712.0K | — |
| Dec 9, 2024 | $-9491.52 | — | $406.9K | — |
News
Echo Tabletop Priced at $11,950 and Echo Full Body at $59,950; First Production Run of 250 Units Available for 2027 Delivery; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp.
CINCINNATI, Ohio, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”), today announced that its Board of Directors has approved a one-for-ten (1-for-10) reverse stock split of the Company's outstanding common stock. The reverse split is expected to become effective at 12:01 a.m. Eastern Time on November 6, 2026. The Company's common stock has been assigned a new CUSIP number, 68237Q500, in connection with the reverse stock split.
Additional $500,000 Advance to Support Growth Initiatives and Working Capital of Realbotix LLC Total Drawn Under Facility Now $3,000,000; Non-Interest Bearing Facility Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition CINCINNATI, Ohio, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) today announced that it has made an additional advance of $500,000 to Realbotix LLC (“Realbotix”), the target of its previously announc…
LAS VEGAS--(BUSINESS WIRE)--Realbotix Corp. (TSX-V: XBOT) (Frankfurt: 76M0.F) (OTC: XBOTF) (“Realbotix” or the “Company”), a leader in humanoid robotics and embodied AI, announces that its wholly owned subsidiary, Realbotix LLC, has agreed to an additional advance of US$500,000 in connection with the loan agreement entered into with Onconetix, Inc. (“Onconetix”) on September 14, 2026 in connection with the proposed merger transaction involving Realbotix LLC and Onconetix previously announced on.
Alnylam Pharmaceuticals (NASDAQ: ALNY - Get Free Report) and Onconetix (NASDAQ: ONCO - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation. Insider and Institutional Ownership 93.0% of Alnylam Pharmaceuticals shares
SRX has added ONCO in anticipation of Realbotix LLC acquisition closing. Believes Vinci AI Vision system is extremely undervalued and misunderstood, with multiple potential applications in defense, ranging from drones for facial recognition to body cameras. SRX has added ONCO in anticipation of Realbotix LLC acquisition closing. Believes Vinci AI Vision system is extremely undervalued and misunderstood, with multiple potential applications in defense, ranging from drones for facial recognition t…
Initial Advance of $2.5 Million to Realbotix LLC to Support Growth and Working Capital; Non-Interest Bearing Facility Is Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition
Initial Advance of $2.5 Million to Realbotix LLC to Support Growth and Working Capital; Non-Interest Bearing Facility Is Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition
LAS VEGAS--(BUSINESS WIRE)--Realbotix Corp. (TSX-V: XBOT) (Frankfurt: 76M0.F) (OTC: XBOTF) (“Realbotix” or the “Company”), a leader in humanoid robotics and embodied AI, announces that its wholly owned subsidiary, Realbotix LLC, has entered into a loan agreement with Onconetix, Inc. (“Onconetix”) for an unsecured bridge loan facility in connection with the proposed merger transaction involving Realbotix LLC and Onconetix previously announced on February 12, 2026. The bridge loan provides transa.
Pilot Tests Humanoid Robots as Presenters, Hosts, and Brand Ambassadors Before Live Audiences, Extending Robot Capabilities Beyond One-on-One Interaction into Dynamic, Audience-Facing Environments; Onconetix Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp.